Quick Comparison
| Huperzine A | Sunifiram | |
|---|---|---|
| Half-Life | 10-14 hours | Estimated 1-2 hours (limited data) |
| Typical Dosage | Standard: 50-200 mcg once or twice daily. Due to the long half-life, cycling is recommended (2 weeks on, 1 week off). Do not combine with prescription acetylcholinesterase inhibitors (donepezil, rivastigmine). | Standard: 4-8 mg sublingually. Active doses are very small — do NOT dose by weight equivalence with piracetam. Start at 4 mg. Do not use daily due to lack of long-term data. Sublingual preferred for consistent absorption. |
| Administration | Oral (capsules, tablets). Well-absorbed orally. | Sublingual (preferred) or oral. Very small doses — requires a milligram scale for accurate dosing. |
| Research Papers | 10 papers | 10 papers |
| Categories |
Mechanism of Action
Huperzine A
Huperzine A is a potent, selective, and reversible inhibitor of acetylcholinesterase (AChE), binding to the enzyme's active site and preventing hydrolysis of acetylcholine to choline and acetate. By blocking AChE, it increases acetylcholine concentration in the synaptic cleft, prolonging activation of muscarinic (M1-M5) and nicotinic receptors. Huperzine A also blocks NMDA glutamate receptors in a non-competitive, use-dependent manner (similar to memantine), binding to the phencyclidine site within the ion channel and protecting neurons from excitotoxic calcium influx. It shows selectivity for the NR2A and NR2B subunits. Additionally, huperzine A has antioxidant properties, scavenging reactive oxygen species and reducing lipid peroxidation. It may enhance NGF signaling.
Sunifiram
Sunifiram (DM-235) is a positive allosteric modulator of AMPA receptors (GluA1-4 subunits) — an ampakine that slows receptor desensitization and deactivation, enhancing glutamatergic excitatory neurotransmission and calcium influx through the receptor. This calcium influx activates CaMKII (calcium/calmodulin-dependent protein kinase II), which phosphorylates GluA1 at Ser831 and is a key enzyme in long-term potentiation (LTP) and memory consolidation. Sunifiram also activates protein kinase C (PKC) isoforms, which phosphorylate GluA2 and regulate receptor trafficking. It increases acetylcholine release in the prefrontal cortex and hippocampus, likely via presynaptic nicotinic receptor activation or enhanced glutamatergic drive onto cholinergic neurons. Downstream, these mechanisms enhance CREB phosphorylation, Arc expression, and synaptic AMPA receptor insertion — the molecular basis of memory formation.
Risks & Safety
Huperzine A
Common
Nausea, diarrhea, sweating, muscle twitching.
Serious
Cholinergic crisis at high doses (excessive acetylcholine causing muscle weakness, breathing difficulty).
Rare
Blurred vision, slowed heart rate, seizures.
Sunifiram
Common
Overstimulation, headache, jaw clenching at higher doses.
Serious
No long-term human safety data. Animal studies show a wide therapeutic index.
Rare
Insomnia, anxiety, irritability.
Full Profiles
Huperzine A →
A naturally occurring alkaloid extracted from Chinese club moss (Huperzia serrata). It powerfully inhibits acetylcholinesterase — the enzyme that breaks down acetylcholine — resulting in significantly elevated acetylcholine levels in the brain. Used in Chinese medicine for centuries and now studied worldwide for Alzheimer's disease.
Sunifiram →
An experimental ampakine compound structurally related to piracetam but estimated to be 1,000x more potent. Sunifiram enhances AMPA receptor function, increases long-term potentiation in the hippocampus, and activates CaMKII and PKC signaling — molecular processes directly involved in memory formation. It has a noticeable acute effect on focus and memory, but very limited human safety data.